Figure 3.

Hepatocyte TMEM16A aggravates HFD‐induced obesity and insulin resistance. A) Body weight of TM^LTg and TM^con mice on the indicated diets for 32 weeks. *P < 0.05 versus TM^con chow, #P < 0.05 versus TM^con HFD, n = 15–20 per group. B) Weight of iBAT and iWAT of TM^con and TM^LTg mice after HFD treatment. #P < 0.05 versus TM^con HFD, n = 8 per group. C) Representative images of H&E staining of iBAT and iWAT. Adipocyte diameter was calculated. Scale bar, 50 µm. #P < 0.05 versus TM^con HFD, n = 8 per group. D) PAS staining representative images of liver sections of TM^con and TM^LTg mice on the indicated diets, n = 4 per group. Scale bar, 50 µm. E,F) Hepatic glycogen content (E), fasting blood glucose, fasting insulin, and HOMA‐IR index (F) in TM^con and TM^LTg mice on the indicated diets for 32 weeks. *P < 0.05 versus TM^con chow, #P < 0.05 versus TM^con HFD, n = 12 per group. G,H) GTT (G) and ITT (H) were performed on TM^con and TM^LTg mice after 32 weeks on the indicated diets. *P < 0.05 versus TM^con chow, #P < 0.05 versus TM^con HFD, n = 14 per group. I) Phosphorylation of IRS1 (Tyr608, Ser307), AKT (Ser473), and mTOR (Ser2448) in response to an intraperitoneal injection of saline or insulin (1.0 IU kg⁻¹ for 15 min) in the liver tissues of TM^con and TM^LTg mice after being fed with HFD. #P < 0.05 versus TM^con insulin, n = 6 per group.